MiRus

MiRus is a privately-held medical device innovator founded in 2007, built around its patented MoRe® alloy, which offers superior strength, biocompatibility, and reduced metal ion release compared to traditional materials like titanium. The company has successfully transitioned multiple products to the commercial stage, with a growing pipeline in spine, orthopedics, and transcatheter heart valves, as evidenced by recent FDA clearances and a New Technology Add-on Payment (NTAP). Operating as an integrated platform company, MiRus combines novel biomaterials, implant design, procedural solutions, and remote monitoring to improve patient outcomes across the continuum of care.

Proprietary MoRe® (Molybdenum-Rhenium) superalloy enabling smaller, stronger, more biocompatible implants with lower metal ion release, integrated with novel implant designs, procedural solutions, and remote physiologic monitoring systems.

In orthopedics and spine, MiRus competes with large, established players like Medtronic, Stryker, and Johnson & Johnson. In the high-growth TAVR market, it would face intense competition from industry leaders Edwards Lifesciences and Medtronic, who dominate with extensive clinical data and sales networks.